Drug use and design in the nineties.
Trigg
P I
PI
Malaria Unit, World Health Organization, Geneva, Switzerland.
D000634:Aminoquinolines / Q000627:therapeutic use; D000655:Amodiaquine / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002738:Chloroquine / Q000627:therapeutic use; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000517:prevention & control; D015767:Mefloquine / Q000627:therapeutic use; D009285:Naphthoquinones / Q000627:therapeutic use; D010616:Phenanthrenes / Q000627:therapeutic use; D011319:Primaquine / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D012717:Sesquiterpenes / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use
D000634:Aminoquinolines; D000962:Antimalarials; D037621:Artemisinins; D002121:Calcium Channel Blockers; D009285:Naphthoquinones; D010616:Phenanthrenes; D012717:Sesquiterpenes; D000655:Amodiaquine; C055852:tafenoquine; D013413:Sulfadoxine; D002738:Chloroquine; C031327:artemisinin; D011803:Quinine; D011319:Primaquine; C023768:halofantrine; D015767:Mefloquine